**Epigenetics for Precision Medicine**

The last decade has seen an explosion in the application of precision medicine strategies in the life science industry, from drug development to clinical trial design. The ability to use molecular tools to identify patients who are more or less likely to respond to therapeutic intervention has tremendous commercial, social, and economic benefits. While several approaches using different molecular measurement techniques have been historically used with different levels of success, one that has gained particular traction in recent years is the assessment of epigenomic changes.

The packaging of chromosomal DNA plays a critical role in the epigenetic regulation of the whole genome. It ensures effective storage, access to genetic information and its regulation by the complex protein machinery utilized in gene expression. Known also as ‘gene loops’, ‘long-range chromosomal interactions’ and ‘chromatin domains’, chromosome conformations have been recognized as an essential high-level framework of epigenetic regulation imposed across the whole genome.

*EpiSwitch* is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ ("CCSs"). CCSs provide a compelling, stable framework from which changes in the regulation of a genome can be analyzed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities.

![Diagram of gene looping](image)

**Figure 1**: The higher order, three-dimensional structure of DNA includes chromosome conformations, or “gene loops” that bring genomic loci that are distant from each other in linear space into close spatial proximity.
When considering both cis (between genomic regions on the same chromosome) and trans interactions (between genomic regions on different chromosomes), there are on the order of billions of potential interactions that can be experimentally measured. While this make for a rich pool of candidate biomarkers, the sheer size of the pool makes measuring every single potential interaction experimentally overbearing. There are, however, ways to screen a large pool of potential interactions in a high-throughput fashion to identify a subset of markers of interest for any given stratification question, whether its identifying responders and non-responders to a therapeutic intervention, identifying markers of disease onset or progression, or assessing markers that track with a bodies changes in response to training programs or recovery from sport traumas.

OBD uses a three-stage approach to screen, identify, evaluate and validate CCSs, ensuring that the biomarker panels that emerge from this pipeline are biologically vetted and statistically robust to be used in pre-clinical and clinical practice. The following provides a step-by-step explanation of OBDs’ *EpiSwitch* biomarker discovery platform, from initial design to validation.

**Figure 2:** Oxford BioDynamics’ three-step biomarker discovery workflow using the *EpiSwitch* platform technology.

**STAGE 1 – DESIGN**

**EpiSwitch Design Annotation**

In this stage, the proprietary annotations of over 1 million *EpiSwitch* sites hidden within the genome, are mapped for the loci of interest, matching them as anchoring points of framework regulation across the genes, SNPs, enhancers, sites of transcriptional relevance, sites of regulatory histone modifications and other loci of potential functional importance. This generates a reliable and manageable list of chromosomal interactions for further analysis. In essence, this step serves as a feature reduction exercise to home in on the most biologically meaningful interactions. The approach to deriving the short list is defined collaboratively between OBD and its partners and depends on the nature and scope of the research question at hand. For example, if the goal is to identify a set of markers that shed light on the mechanism of response to an immuno-oncology drug with a defined target (e.g. PD-1 or PD-L1), genomic loci encoding proteins implicated in the known
pathways and signaling cascades of PD-1/PD-L1 may be selected. In contrast, if the goal is to identify a biomarker of disease onset in a condition with a known inflammatory component, such as ALS, genomic loci encoding proteins involved in regulating the immune system (cytokines, chemokines, MHC proteins) may be selected. At this stage, between 200-400 genomic regions are identified and processed by OBDs proprietary pattern recognition algorithm to identify the Episwitch sites contained in these regions, typically on the order of around 14,000 sites. Importantly, the genomic regions selected in this stage need not be restricted to only those that are protein-encoding; non-coding regions, regulatory regions, regions encoding non-coding RNAs and genetic variants can be used as well.

**STAGE 2 – DISCOVER**

*Episwitch CGH Arrays and MIQE-compliant qPCR*

Once the Episwitch sites for the study are identified, the next step is to measure which of these sites form chromosome long range interactions and show the conditional nature for the stratification question at hand. Remember, the Episwitch sites identified in Stage 1 are predicted interaction sites and need two additional steps. First is experimental confirmation of detectable chromosome loops (over 90% of annotated sites form detectable interactions when tested) and second, if the chromosome loops are conditional. That is, can they differentiate between compared phenotypes (e.g. disease vs. non-disease, responder vs. non-responder, fast progressors vs slow progressors).

![Figure 3: A simplified workflow for detecting chromosome conformations by microarray or PCR.](image)

Molecular biology offers several methods to detect long range chromosomal conformations. The underlying principle allows for the capture of distant genomic juxtapositions by first stabilizing distant sites within intact cell nuclei, then isolating them and converting them into an artificial template with distant fragments of genome ligated to each other in one DNA product and detecting the new products as evidence of long range interactions. Early research protocols called chromosome conformation capture (3C) were developed in 2002, which were followed over the years by several other variants aimed at assessing different scopes and levels of chromosome conformations. These protocols are used widely in academic settings today. Although all are very useful in providing insights and evidence for specific interactions, they remain time and labor consuming, often with low resolution and frequent variability in readouts. The proprietary protocols used in processing and detection of long range interactions used by Episwitch in the analysis of clinical samples and other cellular inputs have taken screening and monitoring of chromosome conformations to a different level in terms of industry standards: speed, cost, sensitivity, resolution, accuracy and robustness. Conversion of epigenetic analytes into sequence-based readouts is conducted within hours, on robotic platforms and in high throughput. Final quantitated readouts for individual markers and validated stratifying signatures are performed either in the simple format of binary nested PCR or in the format of MIQE-compliant qPCR with proprietary hydrolysable probe design.
Stage 2 is dedicated to screening for biomarker leads in a high-throughput approach using a customized microarray containing readouts for the ~14,000 potential interactions annotated in the design stage (Stage 1). Next, biospecimen samples (whole blood, PBMCs, cell lines) from two phenotypic comparisons (baseline responders and non-responders, or fast and slow ALS, for example) are competitively hybridized to the custom-designed Agilent CGH SurePrint 180K array. Resulting readouts from biological and technical repeats are put through a series of statistical filters to determine the subset of interactions that can discriminate between the different conditions. This top statistically significant disseminating marker leads of conditional chromosome conformations (typically on the order of a few hundred) is then translated into EpiSwitch PCR detection, enabling faster and lower cost marker reduction on the expended patient cohorts. By iteratively comparing the interactions that can differentiate between two conditions in this sequence-based approach, a final set of interactions (typically between 5 and 10) is identified with machine learning-based methodology. This resulting ‘chromosome conformation signature’ is a molecular barcode that discriminates the epigenetic landscape and network regulation between the two compared patient groups. It reflects heterogeneous impact of external environmental cues on patients genome regulation at the very sites related to the disease and the manifested difference between two compared cohorts.

STAGE 3 – VALIDATE

**EpiSwitch PCR Platform**

In the final stage, the signature identified in Stage 2 is validated on an independent sample cohort. This meets the criteria of independent validation or “proof” required by industry and ensures that the resulting biomarker panel is robust across the broad, real-world patient populations that will be assessed in future studies.

**Case Study: Therapeutic Response Biomarker**

Now that we’ve learned about how the Oxford BioDynamics *EpiSwitch* discovery platform works from a conceptual standpoint, let’s see how the process comes together in a real-world example. Recently, OBD partnered with a Top 10 pharmaceutical company and a leading academic consortium to solve one of the major unmet clinical needs in rheumatoid disease. Rheumatoid arthritis (RA) is an autoimmune inflammatory disorder that manifests clinically as painful, swollen, tender and stiff joints. For patients diagnosed with RA, methotrexate (MTX) is the first choice of disease modifying anti-rheumatic drug (DMARD) as recommended by European League against Rheumatism (EULAR) and American College of Rheumatology (ACR). While MTX has therapeutic benefit in some patients, approximately 35–59% of patients do not achieve clinically meaningful responses after starting therapy.

Over the last several years, a range of newer targeted biologic drugs have been developed and approved for RA, many of which show substantial clinical benefit. Thus, having a mechanism to identify patients who are likely non-responders to MTX would facilitate earlier access to these more effective therapies, thus avoiding disease progression, unnecessary exposure to potentially toxic drugs and diminished quality of life. Using blood samples from the Scottish Early Rheumatoid Arthritis Inception cohort, in the Design step, we evaluated chromosomal

![Figure 3: An example of a chromosome conformation signature (CCS) used to identify non-responders to methotrexate in Rheumatoid Arthritis.](image-url)
interactions at 123 genomic loci selected from a systematic literature review for genes that have been associated with RA. These loci were processed through the OBD pattern recognition software, generating 13,322 chromosomal interactions that were screened for association with response to MTX in RA. In the Discovery step, we used blood samples from RA patients and control samples in a series of comparisons that used statistical filters to refine the 13,332 chromosomal interactions to five interactions (in IFNAR1, IL-21R, IL-23, IL-17A, and CXCL13 loci) that could accurately predict response to MTX. In the Validation step, we applied the 5-marker panel to an independent, blinded cohort of RA patients and asked how well the biomarker panel could identify non-responders to MTX prior to initiating therapy. In this independent cohort, we were able to positive predictive value of over 90%, showing that the use of a CCS has practical utility as a predictive clinical tool.

This study has been published in The Journal of Translational Medicine and can be found here.

Oxford Biodynamics has built extensive expertise and knowledge on the biomarker value for chromosome conformation signatures with a broad spectrum of successful applications in a variety of therapeutic areas including oncology (Melanoma, Lung cancer, Breast cancer, DLBCL and AML), immunology (Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Ulcerative Colitis and Fibrosis) and neurology (Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Huntington’s Disease and Depression).

References

Authors
Willem Westra, PhD
Ewan Hunter, PhD
Alexandre Akoulitchev, PhD

Oxford BioDynamics, Plc
Oxford, United Kingdom
info@oxfordbiodynamics.com